Vivos Therapeutics, Inc. (VVOS) Q2 2024 Annual Earnings
VVOS·Reported August 14, 2024·Before market open
Vivos Therapeutics, Inc. reported Q2 2024 revenue of $4.1M, beat analyst consensus of $3.6M by $454.0K. Diluted EPS came in at $-0.60, beat the $-1.05 consensus by $0.45.
Revenue
$4.1Mbeat by $454.0K
Consensus: $3.6MDiluted EPS
$-0.60beat by $0.45
Consensus: $-1.05
Financial Snapshot
Trailing eight quarters through Q2 2024
Q2 2024 Earnings FAQ
Common questions about Vivos Therapeutics, Inc.'s Q2 2024 earnings report.
Vivos Therapeutics, Inc. (VVOS) reported Q2 2024 earnings on August 14, 2024 before market open.
Vivos Therapeutics, Inc. reported revenue of $4.1M and diluted EPS of $-0.60 for Q2 2024.
Revenue beat the consensus estimate of $3.6M by $454.0K. EPS beat the consensus estimate of $-1.05 by $0.45.
You can read the 10-K/A periodic report (0001493152-24-029491) directly on SEC EDGAR. The filing index links above go to sec.gov.